Valcare Medical, an Accelmed Portfolio Company, Announces Successful First-In-Human Procedures of the Amend™ Catheter Delivered Annuloplasty Ring
Congratulations to Valcare Medical and Accelmed on its Successful First-In-Human Procedures of the Amend™ Catheter Delivered Annuloplasty Ring!
We are honored to have represented Valcare Medical and Accelmed in this meaningful and revolutionary journey.
For more information, please click here.
About Valcare Medical:
Valcare Medical, an Accelmed portfolio company, the developer of novel medical devices for minimally invasive treatment of Mitral Valve Regurgitation, announced today the successful completion of first phase of the its First-In-Human (FIH) multi-center clinical trial, taking place in Israel and Europe.
Valcare developed The Amend™ Mitral Valve Repair Annuloplasty ring, a semi-rigid, a ‘D’ shaped ring that emulates the current gold standard for patients who suffer from Mitral Valve Regurgitation (the valve that controls blood flow between the left atrium and left ventricle). In a series of cases, the ring was successfully Trans apically delivered through an advanced, catheter-based delivery system, and was secured to the annulus by a series of novel integral anchors.
For more information about Valcare Medical, please click here.